Affymetrix Closes eBioscience Deal - Analyst Blog

By
A A A

On June 25, genetic products maker Affymetrix Inc ( AFFX ) completed its acquisition of eBioscience Holding Company, Inc. for $315 million in cash. The payment was partly financed through available cash resources and partly by a public offering of senior notes. eBioscience is now a fully-owned subsidiary of Affymetrix.

Also, Affymetrix's Compensation Committee agreed to issue about 1.32 million shares from its common stock as equity incentive awards to encourage 278 eBioscience employees to join the company.

San Diego, California-based eBioscience has been a global leader in immunology and oncology flow cytometry reagents offering a vast selection of antibodies, enzyme-linked immunosorbent assays ("ELISAs") and proteins for life science research and diagnostics. eBioscience has also been an industry leader in flow cytometry (a technique for analysing microscopic particles) and immunoassay reagents for immunology and oncology research and diagnostics.

The acquisition is expected to significantly boost Affymetrix's foothold in the fast-growing immunology, oncology and translational medicine markets, representing an annual opportunity of more than $2.5 billion. It will diversify the company's revenue base, expand its product range (to include a vast array of reagents) and reinforce its growing molecular diagnostics business.

Management believes that the merger will increase the company's operating income and gross margin in fiscal 2012. Besides expanding its global reach, Affymetrix aims to exploit cross-selling opportunities and invest in research and development ("R&D") to develop new products using eBioscience's technology.

Affymetrix is a leading provider of microarray-based products and services to the global research community. Along with Illumina Inc . ( ILMN ), it is one of the two major providers of microarray technologies, primarily used in the field of genetic research.

The company, however, needs to successfully integrate its acquisitions so that they do not turn out to be a waste. Affymetrix is operating in an intensely competitive industry and faces risks associated with lower R&D spending by its customers due to a soft economy and government actions including budget cuts.


 
AFFYMETRIX INC (AFFX): Free Stock Analysis Report
 
ILLUMINA INC (ILMN): Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research



The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.



This article appears in: Investing , Business , Stocks

Referenced Stocks: AFFX , ILMN

Zacks.com

Zacks.com

More from Zacks.com:

Related Videos

Tiny Homes With Big Appeal
Tiny Homes With Big Appeal          

Stocks

Referenced

100%
100%

Most Active by Volume

270,887,127
    $93.89 unch
225,243,115
  • $40.93 ▼ 2.74%
135,900,109
  • $47.52 ▲ 1.80%
89,467,924
  • $5.35 ▼ 1.11%
85,105,358
  • $16.95 ▼ 0.53%
80,748,539
  • $39.80 ▼ 4.21%
68,491,586
  • $3.57 ▼ 1.79%
62,097,356
  • $100.96 ▼ 0.82%
As of 9/19/2014, 04:15 PM

Find a Credit Card

Select a credit card product by:
Select an offer:
Search
Data Provided by BankRate.com